The aim of this study was to evaluate the value of scheduled imaging for patients who achieved first complete remission after CHOP-like chemotherapy plus rituximab. In this retrospective cohort study, we included 759 patients newly diagnosed with de novo diffuse large B-cell lymphoma (DLBCL) at the Cancer Institute, Japanese Foundation for Cancer Research. Relapsed patients were divided into two groups based on method of diagnosis: clinical symptoms (symptom group, n = 57) or scheduled imaging (imaging group, n = 27). Our primary goal was to compare overall survival and relapse-free survival between the two groups. No significant difference in outcomes was found between the symptom and imaging groups. Median overall survival [7.5 years; 95% confidence interval (CI) 4.0-9.7 vs. 9.1 years; 95% CI 2.7 to not reached; P = 0.747), and median relapse-free survival (1.8 years; 95% CI 1.4-2.5 vs. 2.4 years; 95% CI 1.2-4.4; P = 0.108). Surveillance imaging in patients with DLBCL who achieved first complete remission did not demonstrate an advantage in terms of overall survival or relapse-free survival.

中文翻译：

---

回顾性队列研究显示，对于首次完全缓解的弥漫性大B细胞淋巴瘤患者，监视影像学意义不大。

这项研究的目的是评估CHOP样化学疗法加利妥昔单抗后首次完全缓解的计划影像学的价值。在这项回顾性队列研究中，我们纳入了759例在日本癌症研究基金会癌症研究所新诊断为从头扩散性大B细胞淋巴瘤（DLBCL）的患者。复发患者根据诊断方法分为两组：临床症状（症状组，n = 57）或定期影像学检查（影像组，n = 27）。我们的主要目标是比较两组的总生存期和无复发生存期。症状组和影像学组之间的转归没有显着差异。中位总体生存期[7.5年；95％的置信区间（CI）4.0-9.7与9.1年；95％CI 2.7未达到; P = 0.747），和中位无复发生存期（1.8年； 95％CI为1.4-2.5与2.4年； 95％CI为1.2-4.4； P = 0.108）。首次完全缓解的DLBCL患者的监护影像学未显示出总生存或无复发生存的优势。